OXCT1 and neoplasm: Although we demonstrate that CD8+ T cells are required for the anti-tumour effects of DR, the Cd4-Cre model used in our study deletes Bdh1 and Oxct1 in both CD4+ and CD8+ T cell lineages; therefore, we cannot exclude a contribution of ketolysis in CD4+ T cells to the observed effects.